Collagenase G and Collagenase H compositions for the treatment of diseases involving alterations of collagen
Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or retractable scars.
1. A composition comprising recombinant Collagenase G and recombinant Collagenase H having a mass ratio between 1:2.5 and 1:3.5, wherein the recombinant Collagenase G has the amino acid sequence of SEQ ID NO: 1 and the recombinant Collagenase H has the amino acid sequence SEQ ID NO: 2.
2. A kit comprising recombinant Collagenase G and recombinant Collagenase H having a mass ratio between 1:2.5 and 1:3.5, wherein the recombinant Collagenase G has the amino acid sequence of SEQ ID NO: 1 and the recombinant Collagenase H has the amino acid sequence SEQ ID NO: 2.
3. The composition according to claim 1 , wherein the recombinant Collagenase G and/or recombinant collagenase H have a 6-histidine tag located at the C-terminus of their amino acid sequence.
4. The composition according to claim 1 , wherein the composition is a pharmaceutical composition.
5. The composition according to claim 1 , which also comprises a pharmaceutically acceptable carrier.
6. The composition according to claim 1 , further comprising another active ingredient.
7. A pharmaceutical composition comprising the composition according to claim 1 .
8. The pharmaceutical composition according to the claim 7 which is selected from the group consisting of: plasters, ointment, paste, cream, solution, suspension, emulsion, lotion, liniment, jelly, gel, foam, powder, and any combination thereof.
9. The pharmaceutical composition according to claim 7 , comprising hyaluronic acid in concentrations of between 0.05% and 4%.
10. The pharmaceutical composition according to claim 9 , wherein the hyaluronic acid is in a concentration of about 1.5%.
11. The pharmaceutical composition according to claim 9 , wherein the concentrations of collagenases are higher than 400 CDU/mg of hyaluronic acid.
12. The pharmaceutical composition according to claim 9 , wherein the concentrations of collagenases ranges between 450 and 5000 CDU/mg of hyaluronic acid.
13. The pharmaceutical composition according to claim 9 , wherein the hyaluronic acid has a molecular weight between 500 and 5,000 kDa.
14. The pharmaceutical composition according to claim 9 , wherein the hyaluronic acid has a molecular weight of approximately 850 kDa.
15. The composition according to claim 1 , for use as a medicament.
16. A method for the treatment of diseases involving alterations in connective tissue or fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount of the kit according to claim 2 .
17. A method for the treatment of diseases involving alterations in connective tissue, said method comprising administering to a subject in need thereof a therapeutically effective amount of the composition according to claim 1 .
18. A method for the treatment of fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount of the composition according to claim 1 .
19. The method according to claim 18 , wherein the fibromatosis is selected from the group consisting of: palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or plantar fascial fibromatosis, and retractable scars.
20. A method for the treatment of diseases involving alterations in connective tissue or fibromatosis, said method comprising administering to a subject in need thereof a therapeutically effective amount a kit according to claim 2 , said method comprising administering collagenase G before or simultaneously with collagenase H.